TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8657050

Group type: EXPERIMENTAL
Intervention: Low maintenance doses of clozapine with concomitant neuroleptic therapy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Classical neuroleptics
Number of subjects: 27
Study: 2185008

Group type: EXPERIMENTAL
Intervention: Clemastine hydrogen fumarate
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isoprenaline sulfate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 525647

Group type: EXPERIMENTAL
Intervention: Neomycin sulfate (500 mg, two tablets)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Spironolactone (100 mg tablet)
Number of subjects: 12
Study: 30585832

Group type: COMPARATOR
Intervention: Acetylsalicylic acid prophylaxis (80 mg daily for 14 days)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid treatment (80 mg daily for 7 days between challenges)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ex vivo exposure of platelets to acetylsalicylic acid
Number of subjects: 34
Study: 30075739

Group type: EXPERIMENTAL
Intervention: Digital Counselling Application (DCA) used by intervention providers after a two-day training program.
Number of subjects: 2625

Group type: COMPARATOR
Intervention: Usual care (control group) where providers counsel clients as before without DCA.
Number of subjects: 2625

Group type: EXPERIMENTAL
Intervention: Digital Counselling Application (DCA) used by intervention providers.
Number of subjects: 2625
Study: 27626517

Group type: EXPERIMENTAL
Intervention: HZ/su vaccine
Number of subjects: 13900

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13900
Study: 25218523

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 4% prilocaine with 1:200,000 epinephrine
Number of subjects: 60
Study: 23146657

Group type: EXPERIMENTAL
Intervention: Mastoscopic axillary lymph node dissection (MALND)
Number of subjects: 1027

Group type: COMPARATOR
Intervention: Conventional axillary lymph node dissection (CALND)
Number of subjects: 1027
Study: 20605014

Group type: EXPERIMENTAL
Intervention: Tonal melodies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random melodies
Number of subjects: 0
Study: 17426908

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (500 mg for 5 days)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: IVIg + methylprednisolone
Number of subjects: 223

Group type: COMPARATOR
Intervention: IVIg + placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pain symptoms
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pain severity
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Pain symptoms before randomization
Number of subjects: 223
Study: 15593293

Group type: EXPERIMENTAL
Intervention: Prolene Hernia System
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Mesh Plug Repair
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Lichtenstein Method
Number of subjects: 334

Group type: COMPARATOR
Intervention: Control Group (not specified)
Number of subjects: 334
Study: 11306340

Group type: EXPERIMENTAL
Intervention: Current heavy smokers
Number of subjects: 39876

Group type: EXPERIMENTAL
Intervention: Nonsmoking women passively exposed to cigarette smoke
Number of subjects: 39876

Group type: COMPARATOR
Intervention: Nonsmoking women not exposed to passive smoke
Number of subjects: 39876
Study: 9513842

Group type: EXPERIMENTAL
Intervention: Assisted hatching
Number of subjects: 20

Group type: COMPARATOR
Intervention: No assisted hatching (Control)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Traditional IVF (Control)
Number of subjects: 20
Study: 8068956

Group type: EXPERIMENTAL
Intervention: Fractionated total body irradiation (1,320 cGy) and high-dose etoposide (60 mg/kg) followed by allogeneic bone marrow transplantation (BMT)
Number of subjects: 94
Study: 3180635

Group type: EXPERIMENTAL
Intervention: Once-daily regimen (2 mg phenobarbital tablet)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Twice-daily regimen (2 mg phenobarbital tablet)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Thrice-daily regimen (2 mg phenobarbital tablet)
Number of subjects: 179
Study: 31085338

Group type: EXPERIMENTAL
Intervention: Lower cut-off value for abnormal FIT result (10 or more μg hemoglobin/g feces)
Number of subjects: 17017

Group type: COMPARATOR
Intervention: Standard cut-off value for abnormal FIT result (20 or more μg hemoglobin/g feces)
Number of subjects: 17017
Study: 31013502

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cytokines (irisin, osteocalcin, adiponectin)
Number of subjects: 0
Study: 28330649

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 3778

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 3778
Study: 26491284

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with 18 µg of tiotropium once daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: Pulmonary rehabilitation alone (control group)
Number of subjects: 84
Study: 23030660

Group type: EXPERIMENTAL
Intervention: BTX‐A (onabotulinumtoxinA)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BTX‐B (rimabotulinumtoxinB)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both BTX‐A and BTX‐B
Number of subjects: 22
Study: 22045675

Group type: EXPERIMENTAL
Intervention: Serum miR-122 in APAP-ALI patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum miR-192 in APAP-ALI patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum miR-218 in APAP-ALI patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum miR-122 in CKD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Serum miR-192 in CKD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation of miR-122 with peak ALT levels in APAP-ALI cohort
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Day 1 serum miR-122 levels in APAP-ALI patients satisfying King's College Criteria (KCC)
Number of subjects: 0
Study: 19345766

Group type: EXPERIMENTAL
Intervention: Home exercise program (n=23)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Physical therapist treatment
Number of subjects: 48
Study: 17227639

Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 350

Group type: COMPARATOR
Intervention: Service screening programmes
Number of subjects: 350

Group type: COMPARATOR
Intervention: Early detection
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Breast screening
Number of subjects: 350

Group type: COMPARATOR
Intervention: Ultrasound screening for liver cancer
Number of subjects: 350
Study: 15320684

Group type: EXPERIMENTAL
Intervention: Unstable isometric maximum force output
Number of subjects: 10

Group type: COMPARATOR
Intervention: Stable conditions
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Concentric contractions
Number of subjects: 10
Study: 10997595

Group type: EXPERIMENTAL
Intervention: Gemifloxacin (third-generation quinolone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quinolones (first to third generations)
Number of subjects: 0
Study: 9459089

Group type: EXPERIMENTAL
Intervention: hMG
Number of subjects: 13

Group type: COMPARATOR
Intervention: recombinant FSH
Number of subjects: 13
Study: 8172088

Group type: EXPERIMENTAL
Intervention: Single oral dose of 2.5 mg (100,000 IU) cholecalciferol (vitamin D3)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189
Study: 2963793

Group type: EXPERIMENTAL
Intervention: Isradipine (2.5 mg three times a day rising to 7.5 mg three times a day)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Nifedipine (5 mg three times a day rising to 20 mg three times a day)
Number of subjects: 11
Study: 30653372

Group type: EXPERIMENTAL
Intervention: Occupational therapy activity pacing intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Typical occupational therapy program (control)
Number of subjects: 100
Study: 30335409

Group type: EXPERIMENTAL
Intervention: Radon messages including smoking information (Study 1)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Radon messages with smoking information (Study 2)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Radon message describing smoking as a lung cancer risk (Study 2)
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Radon message describing smoking's synergistic effect with radon (Study 2)
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Radon messages excluding smoking information (Study 2)
Number of subjects: 1045
Study: 27475625

Group type: EXPERIMENTAL
Intervention: Bilastine 10 mg
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg
Number of subjects: 136

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study: 25288512

Group type: EXPERIMENTAL
Intervention: High-dose cannabis (22 mg THC)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Low-dose cannabis (5.5 mg THC)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 23897243

Group type: EXPERIMENTAL
Intervention: Systemic hypothermia of 33°C for 48 hours
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normothermia of 37°C
Number of subjects: 65
Study: 20220045

Group type: EXPERIMENTAL
Intervention: Regimen A (oral casopitant [150 mg day 1, 50 mg days 2 and 3] and warfarin [days 1-10])
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Regimen B (oral casopitant 60 mg and warfarin [days 1-14])
Number of subjects: 97

Group type: COMPARATOR
Intervention: Both regimens (A and B)
Number of subjects: 97
Study: 18069011

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) at energy density of 0.55 mJ/mm(2) (1000 impulses)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Sham treatment with a dummy electrode
Number of subjects: 46
Study: 17211965

Group type: EXPERIMENTAL
Intervention: FertilityBlend (FB)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 11883992

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9539614

Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (200/0.5) solution
Number of subjects: 750

Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 750
Study: 7840167

Group type: EXPERIMENTAL
Intervention: DHEA (500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2192406

Group type: COMPARATOR
Intervention: buprenorphine 4 micrograms/kg injected i.v. every 4 h (Group I)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: bupivacaine 0.15 ml/kg injected epidurally every 2 h (Group II)
Number of subjects: 75

Group type: COMPARATOR
Intervention: buprenorphine 4 micrograms/kg in 10 ml saline via catheter (Group III)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined regime of bupivacaine and buprenorphine (Group IV)
Number of subjects: 75
Study: 96459

Group type: EXPERIMENTAL
Intervention: Perphenazine enanthate (PE) injections, dosage: 50-150 mg, duration: 2-9 days depending on sex
Number of subjects: 0

Group type: COMPARATOR
Intervention: Biperiden treatment
Number of subjects: 0
Study: 7065831

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Methadyl acetate
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Six-week withdrawal
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard three-week treatment
Number of subjects: 61
Study: 31433782

Group type: EXPERIMENTAL
Intervention: Myrtus communis herbal ointment
Number of subjects: 134

Group type: COMPARATOR
Intervention: Anti-hemorrhoid ointment
Number of subjects: 134
Study: 30237155

Group type: EXPERIMENTAL
Intervention: Immediate compression therapy (multilayer bandaging or compression hosiery, pressure 35 mm Hg)
Number of subjects: 592

Group type: COMPARATOR
Intervention: No compression therapy
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Patients without RVO
Number of subjects: 592

Group type: COMPARATOR
Intervention: Patients with RVO
Number of subjects: 592
Study: 27391519

Group type: EXPERIMENTAL
Intervention: Transseptal suturing after septoplasty (Group A)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Nasal packing with Merocel tampons after septoplasty (Group B)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Both groups (Transseptal suturing and Nasal packing)
Number of subjects: 39
Study: 22467404

Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 60
Study: 22822237

Group type: COMPARATOR
Intervention: Flexibility/Balance/Function exercise (FBF)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Supervised Aerobic Exercise (AE)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Control (home-based exercise)
Number of subjects: 121
Study: 19917869

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (anthracycline/taxane-based)
Number of subjects: 1058
Study: 17391169

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoprolol tartrate
Number of subjects: 0
Study: 15756294

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate fortified fish sauce
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ferrous lactate fortified fish sauce
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ferric ammonium citrate fortified fish sauce
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate fortified fish sauce with citric acid
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ferrous sulfate fortified fish sauce without citric acid
Number of subjects: 10
Study: 12042586

Group type: EXPERIMENTAL
Intervention: HFA-BDP (hydrofluoroalkane beclomethasone dipropionate) at half the daily dose (100 to 200 microg)
Number of subjects: 300

Group type: COMPARATOR
Intervention: CFC-BDP (chlorofluorocarbon beclomethasone dipropionate) + spacer at approximately the same dose (200 to 400 microg)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: HFA-BDP
Number of subjects: 300

Group type: COMPARATOR
Intervention: CFC-BDP + S
Number of subjects: 300
Study: 9461367

Group type: COMPARATOR
Intervention: High serum total cholesterol (TC) levels in females
Number of subjects: 548

Group type: EXPERIMENTAL
Intervention: High total cholesterol levels
Number of subjects: 548
Study: 7620754

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/day
Number of subjects: 398

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 398
Study: 2198635

Group type: COMPARATOR
Intervention: Captopril 50 mg (single dose)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Captopril 50 mg (single dose) + Hydrochlorothiazide 50 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Two doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Three doses of Captopril 50 mg + Hydrochlorothiazide 50 mg
Number of subjects: 88
Study: 363253

Group type: EXPERIMENTAL
Intervention: Regimen CAFVP (Adriamycin, cyclophosphamide, 5-fluorouracil, vincristine, prednisone)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Regimen CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisone)
Number of subjects: 148
Study: 31803980

Group type: EXPERIMENTAL
Intervention: Moderate alcohol consumption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large, multiyear randomized controlled trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health policy recommendations
Number of subjects: 0
Study: 31155415

Group type: EXPERIMENTAL
Intervention: delNS1‐H5N1 vaccine at 6.8 log10 TCID50/subject
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: delNS1‐H5N1 vaccine at 7.5 log10 TCID50/subject
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: delNS1‐H5N1 vaccine after 2nd immunization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28169561

Group type: EXPERIMENTAL
Intervention: Bike desk intervention (4 class hours/week for 5 months)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (normal class hours)
Number of subjects: 44
Study: 26151264

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 371

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study: 23642856

Group type: EXPERIMENTAL
Intervention: Ranibizumab therapy
Number of subjects: 65
Study: 21315873

Group type: EXPERIMENTAL
Intervention: Positive information
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Imagery
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 72
Study: 19765849

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control (no ischemic preconditioning)
Number of subjects: 61
Study: 17223996

Group type: EXPERIMENTAL
Intervention: Dexamethasone + CRH stimulation (1 mg overnight and 2 mg over two days)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Desmopressin stimulation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Dexamethasone + CRH stimulation
Number of subjects: 55
Study: 15129744

Group type: EXPERIMENTAL
Intervention: Cued side of fixation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Uncued locations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Directional bias in IOR effect
Number of subjects: 0
Study: 11960536

Group type: EXPERIMENTAL
Intervention: Primary PCI
Number of subjects: 451

Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 451
Study: 9800534

Group type: EXPERIMENTAL
Intervention: Vibrotactile speech perception aid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hearing aids
Number of subjects: 0
Study: 8562145

Group type: EXPERIMENTAL
Intervention: Randomised consent design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard informed consent
Number of subjects: 0
Study: 2227289

Group type: EXPERIMENTAL
Intervention: Diets containing the most carbohydrate (50%-80%) for 2 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Diets containing the most fat (40%) for 2 weeks
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Altering diets by increasing protein and decreasing carbohydrate content by 30% for 24 hours
Number of subjects: 27

Group type: COMPARATOR
Intervention: Maintaining or altering diets for 24 hours
Number of subjects: 27
Study: 116480

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Glipizide
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 37
Study: 31996235

Group type: EXPERIMENTAL
Intervention: Optimune intervention (12-month access)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 360
Study: 30557099

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim
Number of subjects: 2489
Study: 29888520

Group type: EXPERIMENTAL
Intervention: Behaviour Change Techniques (BCTs) delivered by physiotherapists during SOLAS classes
Number of subjects: 8
Study: 26646074

Group type: EXPERIMENTAL
Intervention: Massage therapy (according to Touch Therapy) for four days from the first day postnatal
Number of subjects: 50

Group type: COMPARATOR
Intervention: Routine care (control group)
Number of subjects: 50
Study: 24931572

Group type: EXPERIMENTAL
Intervention: Bionic pancreas
Number of subjects: 52

Group type: COMPARATOR
Intervention: Insulin pump
Number of subjects: 52
Study: 23011184

Group type: COMPARATOR
Intervention: Ranibizumab 0.3 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ranibizumab 0.5 mg
Number of subjects: 0
Study: 19228234

Group type: EXPERIMENTAL
Intervention: Gold standard treatment (acetaminophen/paracetamol or non-steroidal anti-inflammatory drugs, and exercise and/or physical therapy)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Traditional and non-traditional treatments
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Higher education
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Non-White race
Number of subjects: 212
Study: 17708864

Group type: EXPERIMENTAL
Intervention: Milk intervention
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Calcium intervention
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (calcium supplement)
Number of subjects: 11
Study: 15371985

Group type: EXPERIMENTAL
Intervention: Trimethoprim 160 mg orally twice daily for 4 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg orally once daily for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 11219473

Group type: EXPERIMENTAL
Intervention: Almotriptan 12.5 mg
Number of subjects: 1173

Group type: COMPARATOR
Intervention: Sumatriptan 50 mg
Number of subjects: 1173
Study: 9439556

Group type: EXPERIMENTAL
Intervention: Gliclazide (80 to 320 mg/d) for 2 years
Number of subjects: 5572
Study: 8177670

Group type: EXPERIMENTAL
Intervention: Guided laboratory approach (lab group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Lecture and nonexperimental learner-centered activities (comparison group)
Number of subjects: 46
Study: 2846022

Group type: EXPERIMENTAL
Intervention: Prazosin (0.5 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 6
Study: 31157575

Group type: COMPARATOR
Intervention: Itraconazole pulse therapy (Group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combined long-pulsed Nd:Yag laser and itraconazole pulse therapy (Group II)
Number of subjects: 30
Study: 29701045

Group type: EXPERIMENTAL
Intervention: Subcutaneous embedding of thumb-tack needle combined with mytear
Number of subjects: 80

Group type: COMPARATOR
Intervention: 0.1% sodium hyaluronate eye drop (alice), four times per day for two weeks
Number of subjects: 80
Study: 27062851

Group type: EXPERIMENTAL
Intervention: Percutaneous kyphoplasty (PKP) by unilateral approach (group A)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Percutaneous kyphoplasty (PKP) by bilateral approach (group B)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both unilateral and bilateral approaches
Number of subjects: 22
Study: 24739260

Group type: EXPERIMENTAL
Intervention: 3g/d LCn‐3s
Number of subjects: 153

Group type: COMPARATOR
Intervention: 12-week nutrition and exercise education program plus olive oil (P‐LC)
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: education program plus LCn‐3s (EX+N‐3)
Number of subjects: 153

Group type: COMPARATOR
Intervention: education groups (OO+N‐3)
Number of subjects: 153

Group type: COMPARATOR
Intervention: education program
Number of subjects: 153